Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Net Cash Flow readings, the most recent being -$3.3 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 77.79% to -$3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$36.0 million, a 16.22% decrease, with the full-year FY2025 number at -$47.6 million, down 71.89% from a year prior.
  • Net Cash Flow hit -$3.3 million in Q1 2026 for Barinthus Biotherapeutics, up from -$4.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $13.6 million in Q4 2024 to a low of -$20.0 million in Q2 2023.
  • Median Net Cash Flow over the past 5 years was -$11.2 million (2023), compared with a mean of -$9.0 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 379.25% in 2022 and later crashed 213.33% in 2023.
  • Barinthus Biotherapeutics' Net Cash Flow stood at -$11.4 million in 2022, then tumbled by 68.99% to -$19.3 million in 2023, then soared by 170.55% to $13.6 million in 2024, then plummeted by 131.07% to -$4.2 million in 2025, then increased by 21.91% to -$3.3 million in 2026.
  • The last three reported values for Net Cash Flow were -$3.3 million (Q1 2026), -$4.2 million (Q4 2025), and -$10.3 million (Q3 2025) per Business Quant data.